{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T17:05:10Z","timestamp":1789578310098,"version":"build-2803163510"},"reference-count":20,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T00:00:00Z","timestamp":1773187200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008363","name":"Kr\u00e6ftens Bek\u00e6mpelse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008363","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014841","name":"Medac","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014841","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","euoncology.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Oncology"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.euo.2026.03.008","type":"journal-article","created":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T21:36:23Z","timestamp":1774042583000},"page":"833-840","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["DaBlaCa-13 Study: Five-year Follow-up from the Randomized Controlled Trial of Chemoresection with Intravesical Mitomycin C in Recurrent Ta Non\u2013muscle-invasive Bladder Cancer"],"prefix":"10.1016","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4308-2950","authenticated-orcid":false,"given":"S\u00f8ren","family":"Klingenberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria S.","family":"Lindgren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakob K.","family":"Jakobsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f8rgen B.","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pernille S.","family":"Kingo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euo.2026.03.008_b0005","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.euo.2026.03.008_b0010","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.eururo.2005.12.031","article-title":"Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials","volume":"49","author":"Sylvester","year":"2006","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2026.03.008_b0015","doi-asserted-by":"crossref","first-page":"216","DOI":"10.6004\/jnccn.2024.0024","article-title":"NCCN Guidelines\u00ae insights: bladder cancer, version 3.2024","volume":"22","author":"Flaig","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.euo.2026.03.008_b0020","doi-asserted-by":"crossref","first-page":"2796","DOI":"10.1016\/S0140-6736(16)30512-8","article-title":"Bladder cancer","volume":"388","author":"Kamat","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.euo.2026.03.008_b0025","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.hoc.2021.01.005","article-title":"Real world outcomes of patients with bladder cancer: effectiveness versus efficacy of modern treatment paradigms","volume":"35","author":"Pfail","year":"2021","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.euo.2026.03.008_b0030","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/bju.14915","article-title":"Update on the guideline of guidelines: non-muscle-invasive bladder cancer","volume":"125","author":"Taylor","year":"2020","journal-title":"BJU Int"},{"key":"10.1016\/j.euo.2026.03.008_b0035","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1016\/j.eururo.2020.07.009","article-title":"The DaBlaCa-13 study: short-term, intensive Chemoresection versus Standard adjuvant intravesical instillations in non-muscle-invasive bladder cancer \u2013 a randomised controlled trial","volume":"78","author":"Lindgren","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2026.03.008_b0040","unstructured":"DMCG.dk. Danish bladder cancer guidelines. https:\/\/www.dmcg.dk\/kliniske-retningslinjer\/kliniske-retningslinjer-opdelt-paa-dmcg\/cancer-i-urinvejene\/blaerekraeft\/."},{"key":"10.1016\/j.euo.2026.03.008_b0045","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1200\/JCO.22.00470","article-title":"DaBlaCa-13 study: oncological outcome of short-term, intensive chemoresection with mitomycin in nonmuscle invasive bladder cancer: primary outcome of a randomized controlled trial","volume":"41","author":"Lindgren","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2026.03.008_b0050","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research Electronic Data Capture (REDCap)\u2013a metadata-driven methodology and workflow process for providing translational research informatics support","volume":"42","author":"Harris","year":"2009","journal-title":"J Biomed Inform"},{"key":"10.1016\/j.euo.2026.03.008_b0055","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.eururo.2012.05.032","article-title":"Neoadjuvant short-term intensive intravesical mitomycin C regimen compared with weekly schedule for low-grade recurrent non-muscle-invasive bladder cancer: preliminary results of a randomised phase 2 study","volume":"62","author":"Colombo","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2026.03.008_b0060","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1111\/bju.15038","article-title":"Caliber: a phase II randomized feasibility trial of chemoablation with mitomycin-C vs surgical management in low-risk non-muscle-invasive bladder cancer","volume":"125","author":"Mostafid","year":"2020","journal-title":"BJU Int"},{"key":"10.1016\/j.euo.2026.03.008_b0065","unstructured":"R Core Team. A Language and Environment for Statistical Computing. Vienna, Austria: Foundation for Statistical Computing, https:\/\/www.R-project.org\/."},{"key":"10.1016\/j.euo.2026.03.008_b0070","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.euf.2022.12.003","article-title":"A systematic review and meta-analysis of chemoablation for non-muscle-invasive bladder cancer","volume":"9","author":"Yanagisawa","year":"2023","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.euo.2026.03.008_b0075","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.euo.2018.08.032","article-title":"Chemoablation with intensive intravesical mitomycin C treatment: a new approach for non-muscle-invasive bladder cancer","volume":"2","author":"Racioppi","year":"2019","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euo.2026.03.008_b0080","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/j.euo.2024.06.005","article-title":"The role of mitomycin C in intermediate-risk non-muscle-invasive bladder cancer: a systematic review and meta-analysis","volume":"7","author":"Scilipoti","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euo.2026.03.008_b0085","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.urolonc.2020.06.013","article-title":"Low compliance to guidelines in nonmuscle-invasive bladder carcinoma: a systematic review","volume":"38","author":"Mori","year":"2020","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euo.2026.03.008_b0090","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.eururo.2024.07.027","article-title":"European Association of Urology guidelines on non-muscle-invasive bladder cancer (TaT1 and carcinoma in situ)-a summary of the 2024 guidelines update","volume":"86","author":"Gontero","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2026.03.008_b0095","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1097\/JU.0000000000004296","article-title":"Primary chemoablation of recurrent low-grade intermediate-risk nonmuscle-invasive bladder cancer with UGN-102: a single-arm, open-label, Phase 3 trial (ENVISION)-Label","volume":"213","author":"Prasad","year":"2025","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2026.03.008_b0100","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1097\/JU.0000000000003645","article-title":"Treatment of low-grade intermediate-risk nonmuscle-invasive bladder cancer with UGN-102\u00a0\u00b1\u00a0transurethral resection of bladder tumor compared to transurethral resection of bladder tumor monotherapy: a randomized, controlled, Phase 3 trial (ATLAS)","volume":"210","author":"Prasad","year":"2023","journal-title":"J Urol"}],"container-title":["European Urology Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931126000660?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931126000660?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T16:45:42Z","timestamp":1789577142000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2588931126000660"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":20,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S2588931126000660"],"URL":"https:\/\/doi.org\/10.1016\/j.euo.2026.03.008","relation":{},"ISSN":["2588-9311"],"issn-type":[{"value":"2588-9311","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"DaBlaCa-13 Study: Five-year Follow-up from the Randomized Controlled Trial of Chemoresection with Intravesical Mitomycin C in Recurrent Ta Non\u2013muscle-invasive Bladder Cancer","name":"articletitle","label":"Article Title"},{"value":"European Urology Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euo.2026.03.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}